

DR. S.K. SUNDARAMOORTHY

31.03.2017

To,

Company Secretary

Lotus Eye Hospital and Institute Limited,
770/12, Avinashi Road,
Civil Aerodrome Post,
Coimbatore-641014


Dear Sir,

Sub: Disclosures under Regulation 30(1) and 30(2) of SEBI
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Please find enclosed herewith the Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Kindly acknowledge the same.

Yours faithfully,


(Dr. S.K. Sundaramoorthy)

Encl.: As above


CC:

- 1) BSE Limited
- 2) National Stock Exchange of India Ltd.,

Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	Lotus Eye Hospital and Institute Limited		
2. Name(s) of the stock exchange(s) where the shares of the TC are listed	1. National Stock Exchange of India Ltd. 2. BSE Limited		
3. Particulars of the shareholder(s) : a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b. Name(s) of promoter(s), member of the promoter group and PAC with him	Dr. S.K.Sundaramoorthy		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share /voting capital of TC (*)
As of March 31st of the year, holding of:			
a) Shares	10599920	50.97%	-
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	10599920	50.97%	-


Signature of the Authorised Signatory

Place: Coimbatore

Date: 31.03.2017

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.